Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:
Capnia Inc (NASDAQ:CAPN)’s shares picked up 16.67%, and closed at $8.75, hitting new 52-week high of $9.90.
Formerly on February 27, Capnia, Inc. (CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, recently declared the first U.S. commercial sales of the Corporation’s CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neuro-developmental disorders in newborns.
“We have made noteworthy progress to date with the U.S. commercialization of CoSense, the only accessible device for accurately and non-invasively measuring ETCO in newborns,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia.
Of the 140 million babies born worldwide and 9.2 million babies born annually in the in the U.S. and European Union, more than 60% will present with jaundice at some point in the first five days of life. Jaundice is caused by the pigment bilirubin and may be a sign of excessive breakdown of red blood cells, or hemolysis. In infants, bilirubin is toxic to the brain and central nervous system. Exposure to high levels of bilirubin in newborns may lead to permanent neurological damage. These neurological abnormalities range from subtle ones such as learning disabilities and impaired hearing to severe life threatening outcomes such as acute bilirubin encephalopathy, or a chronic disabling disease called kernicterus.
Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia’s lead product is CoSense, which aids in the detection of hemolysis, a dangerous condition in which red blood cells degrade rapidly.
Coronado Biosciences Inc (NASDAQ:CNDO), raised 15.36%, and closed at $15.36, hitting new 52-week high of $3.73.
Coronado Biosciences, Inc. (CNDO), declared the formation of a new partner corporation, Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber). Dr. Marasco will chair the Scientific Advisory Board of the Corporation. Under the terms of the contract, Checkpoint will pay Dana-Farber an up-front licensing fee in addition to development and sales-based milestone payments and royalties on net sales.
The portfolio of antibodies licensed from Dana-Farber comprises antibodies targeting PD-L1, GITR and CAIX. Checkpoint plans to develop these novel immuno-oncology and checkpoint inhibitor antibodies on their own and in combination with each other, as data suggests that combinations of these targets can work synergistically together. Clinical trials are predictable to start in the second half of next year.
Coronado Biosciences is a biopharmaceutical corporation dedicated to investing in, acquiring, developing and commercializing novel pharmaceutical products. The Corporation’s portfolio comprises novel immunotherapy agents for the treatment of autoimmune diseases and cancer.
Palatin Technologies, Inc (NYSEMKT:PTN), enhanced 15.45%, and closed at $1.27.
Palatin Technologies Inc. (PTN), declared that it has launched a clinical trial website (https://www.reconnectstudy.com) in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD). Palatin initiated Protocols 301 and 302 of its phase 3 clinical trial reconnect study in the United States and Canada for the treatment of FSD in December 2014 and January 2015. Each pivotal trial of the reconnect study is a multicenter (~80 sites), randomized, placebo controlled, parallel-group, eight month trial with an open-label extension phase.
Palatin Technologies, Inc. is a biopharmaceutical corporation developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with noteworthy unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
Sophiris Bio Inc (NASDAQ:SPHS), rose13.06%, and closed at $0.800. The company holds the market capitalization of 11.93M. The stock return on equity value is - 130.70%, while return on assets value is - 94.00%, in response to its return on investment value of - 21.80%. Its 20-day moving average gained 58.78%, and the stock moved above 50-day moving average of 65.51%. The mean recommendation of analysts for this stock is 2.40.(where 1=Buy, 5=Sale).
